Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Adv Sci (Weinh). 2022 Jan;9(3):e2102466. doi: 10.1002/advs.202102466. Epub 2021 Nov 25.

Abstract

Diabetes mellitus (DM) refers to a group of metabolic disorders that are characterized by hyperglycemia. Oral subcutaneously administered antidiabetic drugs such as insulin, glipalamide, and metformin can temporarily balance blood sugar levels, however, long-term administration of these therapies is associated with undesirable side effects on the kidney and liver. In addition, due to overproduction of reactive oxygen species and hyperglycemia-induced macrovascular system damage, diabetics have an increased risk of complications. Fortunately, recent advances in nanomaterials have provided new opportunities for diabetes therapy and diagnosis. This review provides a panoramic overview of the current nanomaterials for the detection of diabetic biomarkers and diabetes treatment. Apart from diabetic sensing mechanisms and antidiabetic activities, the applications of these bioengineered nanoparticles for preventing several diabetic complications are elucidated. This review provides an overall perspective in this field, including current challenges and future trends, which may be helpful in informing the development of novel nanomaterials with new functions and properties for diabetes diagnosis and therapy.

Keywords: acetone sensing; antioxidant; diabetic complications; glucose detection; nanocarrier; wound healing.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Diabetes Complications / drug therapy
  • Diabetes Mellitus / drug therapy*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Nanostructures / therapeutic use*
  • Precision Medicine / methods*

Substances

  • Hypoglycemic Agents